Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension

Journal of the American Society of Hypertension

Volumn 4, Issue 5, 2010, Pages 219-226

  Jones Burton, Charlotte ^a   Rubino, Joseph ^a   Roy, Sophie ^a   Mai, Yabing ^a   Meehan, Alan ^a   Bellet, Marc ^b   Feig, Peter ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Enalapril; Hypertension; MK 8141; Renin inhibition

Indexed keywords

ACT 077825; ENALAPRIL; MK 8141; RENIN; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 77957862004     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2010.06.006     Document Type: Article

References (23)

1. M.A. Weber, R.L. Byyny, J.H. Pratt, E.P. Faison, D.B. Snavely, and A.I. Goldberg Blood pressure effects of the angiotensin II receptor blocker, losartan Arch Intern Med 155 1995 405 411
2. J.A. Staessen, Y. Li, and T. Richart Oral renin inhibitors Lancet 368 2006 1449 1456
3. H. Kruma, and R.E. Gilbert Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders J Hypertens 25 2007 25 35
4. L. Juillerat, J. Nussberger, J. Menard, V. Mooser, Y. Christen, and B. Weber Determinants of angiotensin II generation during converting enzyme inhibition Hypertension 16 1990 564 572
5. V.J. Dzau, K. Bernstein, D. Celermajer, J. Cohen, B. Dahlöf, and J. Deanfield Pathophysiologic and therapeutic importance of tissue ACE: a consensus report Card Drugs Ther 16 2002 149 160
6. S.D. Crowley, S.B. Gurley, M.I. Oliverio, A.K. Pazmino, R. Griffiths, and P.J. Flannery Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system J Clin Invest 115 2005 1092 1099
7. J. Nussberger, G. Wuerzner, C. Jensen, and H.R. Brunner Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril Hypertension 39 2002 e1 e8
8. M. Azizi, A. Bissery, M. Lamarre-Cliché, and J. Menard Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans Hypertension 43 2004 785 790
9. A.H. Gradman, R.E. Schmeider, R.L. Lins, J. Nussberger, Y. Chiang, and M.P. Bedigian Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients Circulation 111 2005 1012 1018
10. A. Villamil, S.G. Chrysant, D. Calhoun, B. Schober, H. Hsu, and L. Matrisciano-Dimichino Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide J Hypertens 25 2007 217 226
11. J.L. Pool, R.E. Schmieder, M. Azizi, J.-C. Aldigier, A. Januszewicz, and W. Zidek Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan Am J Hypertens 20 2007 11 20
12. B.-H. Oh, J. Mitchell, J.R. Herron, J. Chung, M. Khan, and D.L. Keefe Aliskiren, an oral renin inhibitor, provides dose dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension J Am Coll Cardiol 49 2007 1157 1163
13. A. Stanton, C. Jensen, J. Nussberger, and E. O'Brien Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren Hypertension 42 2003 1137 1143
14. E. O'Brien, J. Barton, J. Nussberger, D. Mulcahy, C. Jensen, and P. Dicker Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker Hypertension 49 2007 276 284
15. J. Nussberger, A.H. Gradham, R.E. Schmieder, R.L. Lins, Y. Chiang, and M.F. Prescott Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension Int J Clin Pract 61 2007 1461 1468
16. U.S. product circular for Tekturna (aliskiren). Available online at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/021985lbl.pdf. Accessed July 9, 2010.
17. W. Fischli, J.P. Clozel, V. Breu, S. Buchmann, S. Mathews, and H. Stadler Ciprokiren (Ro-44-9375) - a renin inhibitor with increasing effects on chronic treatment Hypertension 24 1994 163 169
18. J.P. Clozel, W. Fischli, and J. Menard Effects of the blockade of the renin-angiotensin system in cyclosporine-induced hypertension J Hypertens 11 1993 75 81
19. M.O. Behm, J. Dingemanse, L.B. Nicolas, D. Harris, A. Taylor, and A. Treiber A drug-drug interaction study of MK-8141/ACT-077825 co-administered with midazolam to evaluate concurrent CYP3A4 induction and inhibition potential J Clin Pharmacol 49 2009 1113
20. L. Nicolas, C. Binkert, A. Jungnik, and J. Dingemanse Integrated clinical pharmacology of a new renin inhibitor during the first study in humans Clin Pharmacol Ther 85 Suppl 1 2009 S70
21. L.B. Nicolas, C. Binkert, A. Jungnik, M.O. Behm, D.E. Harris, and G. Murphy Clinical pharmacology of multiple ascending doses of ACT-077825/MK-8141, a new renin inhibitor J Clin Pharmacol 49 2009 1110
22. K. Liang, and S. Zeger Longitudinal data analysis of continuous and discrete responses for pre-post designs Sankhya Ind J Stat 62 Series B 2000 134 148
23. J.E. Sealey, and J.H. Laragh Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises Am J Hypertens 22 2009 112 121